Loading…
Biology of FasL
FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of Fas...
Saved in:
Published in: | Cytokine & growth factor reviews 2003-06, Vol.14 (3), p.325-335 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83 |
---|---|
cites | cdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83 |
container_end_page | 335 |
container_issue | 3 |
container_start_page | 325 |
container_title | Cytokine & growth factor reviews |
container_volume | 14 |
creator | Lee, Hae-ock Ferguson, Thomas A. |
description | FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology. |
doi_str_mv | 10.1016/S1359-6101(03)00028-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73353678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359610103000285</els_id><sourcerecordid>18797333</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhnNQbK3iL1B6Ej2s5ju7J9FiVSh4UM8hTSYS2TY16Qr996Yf6LGnGWaemRcehM4JviGYyNs3wkRTydJfYXaNMaZ1JQ5Q_2_cQ8c5f5UFZwIfoR6hqlZCNn109hBiGz9Xw-iHY5MnJ-jQmzbD6a4O0Mf48X30XE1en15G95PKcs6XlfeccOqkB0spAJYWT8nUUYV5LTAljnFiqcEeuLXSOTANazxpJJeSKFOzAbrc_l2k-N1BXupZyBba1swhdlkrxgSTaj9IatUUmBVQbEGbYs4JvF6kMDNppQnWa016o0mvfWjM9EaTFuXuYhfQTWfg_q92jgpwtwWg-PgJkHS2AeYWXEhgl9rFsCfiF-j9dfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18797333</pqid></control><display><type>article</type><title>Biology of FasL</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Lee, Hae-ock ; Ferguson, Thomas A.</creator><creatorcontrib>Lee, Hae-ock ; Ferguson, Thomas A.</creatorcontrib><description>FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.</description><identifier>ISSN: 1359-6101</identifier><identifier>DOI: 10.1016/S1359-6101(03)00028-5</identifier><identifier>PMID: 12787569</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Angiogenesis ; Animals ; Autoantibodies - biosynthesis ; CTL ; Cytotoxicity, Immunologic ; Fas Ligand Protein ; FasL ; Homeostasis ; Humans ; Immune privilege ; Immune Tolerance ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - immunology ; Membrane Glycoproteins - physiology ; Mice ; Mice, Mutant Strains ; Models, Immunological ; Mutation ; Neoplasms - immunology ; Neovascularization, Pathologic ; T-Lymphocytes - immunology ; Tumor progression</subject><ispartof>Cytokine & growth factor reviews, 2003-06, Vol.14 (3), p.325-335</ispartof><rights>2003 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</citedby><cites>FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12787569$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Hae-ock</creatorcontrib><creatorcontrib>Ferguson, Thomas A.</creatorcontrib><title>Biology of FasL</title><title>Cytokine & growth factor reviews</title><addtitle>Cytokine Growth Factor Rev</addtitle><description>FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.</description><subject>Angiogenesis</subject><subject>Animals</subject><subject>Autoantibodies - biosynthesis</subject><subject>CTL</subject><subject>Cytotoxicity, Immunologic</subject><subject>Fas Ligand Protein</subject><subject>FasL</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Immune privilege</subject><subject>Immune Tolerance</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Membrane Glycoproteins - physiology</subject><subject>Mice</subject><subject>Mice, Mutant Strains</subject><subject>Models, Immunological</subject><subject>Mutation</subject><subject>Neoplasms - immunology</subject><subject>Neovascularization, Pathologic</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumor progression</subject><issn>1359-6101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LAzEQhnNQbK3iL1B6Ej2s5ju7J9FiVSh4UM8hTSYS2TY16Qr996Yf6LGnGWaemRcehM4JviGYyNs3wkRTydJfYXaNMaZ1JQ5Q_2_cQ8c5f5UFZwIfoR6hqlZCNn109hBiGz9Xw-iHY5MnJ-jQmzbD6a4O0Mf48X30XE1en15G95PKcs6XlfeccOqkB0spAJYWT8nUUYV5LTAljnFiqcEeuLXSOTANazxpJJeSKFOzAbrc_l2k-N1BXupZyBba1swhdlkrxgSTaj9IatUUmBVQbEGbYs4JvF6kMDNppQnWa016o0mvfWjM9EaTFuXuYhfQTWfg_q92jgpwtwWg-PgJkHS2AeYWXEhgl9rFsCfiF-j9dfw</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>Lee, Hae-ock</creator><creator>Ferguson, Thomas A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20030601</creationdate><title>Biology of FasL</title><author>Lee, Hae-ock ; Ferguson, Thomas A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Angiogenesis</topic><topic>Animals</topic><topic>Autoantibodies - biosynthesis</topic><topic>CTL</topic><topic>Cytotoxicity, Immunologic</topic><topic>Fas Ligand Protein</topic><topic>FasL</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Immune privilege</topic><topic>Immune Tolerance</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Membrane Glycoproteins - physiology</topic><topic>Mice</topic><topic>Mice, Mutant Strains</topic><topic>Models, Immunological</topic><topic>Mutation</topic><topic>Neoplasms - immunology</topic><topic>Neovascularization, Pathologic</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumor progression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Hae-ock</creatorcontrib><creatorcontrib>Ferguson, Thomas A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cytokine & growth factor reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Hae-ock</au><au>Ferguson, Thomas A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biology of FasL</atitle><jtitle>Cytokine & growth factor reviews</jtitle><addtitle>Cytokine Growth Factor Rev</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>14</volume><issue>3</issue><spage>325</spage><epage>335</epage><pages>325-335</pages><issn>1359-6101</issn><abstract>FasL (CD95L) is a well-known and well-characterized death-inducing ligand. Spontaneous mutations in FasL and its cognate receptor Fas (CD95) have helped understand the role of these molecules in the disease. Once thought to be mainly involved in the homeostasis of immune system, the territory of FasL regulation has been expanded to angiogenesis and tumor progression. Here, we review what is currently known about the role of FasL in many areas of biology.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12787569</pmid><doi>10.1016/S1359-6101(03)00028-5</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-6101 |
ispartof | Cytokine & growth factor reviews, 2003-06, Vol.14 (3), p.325-335 |
issn | 1359-6101 |
language | eng |
recordid | cdi_proquest_miscellaneous_73353678 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Angiogenesis Animals Autoantibodies - biosynthesis CTL Cytotoxicity, Immunologic Fas Ligand Protein FasL Homeostasis Humans Immune privilege Immune Tolerance Membrane Glycoproteins - genetics Membrane Glycoproteins - immunology Membrane Glycoproteins - physiology Mice Mice, Mutant Strains Models, Immunological Mutation Neoplasms - immunology Neovascularization, Pathologic T-Lymphocytes - immunology Tumor progression |
title | Biology of FasL |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A51%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biology%20of%20FasL&rft.jtitle=Cytokine%20&%20growth%20factor%20reviews&rft.au=Lee,%20Hae-ock&rft.date=2003-06-01&rft.volume=14&rft.issue=3&rft.spage=325&rft.epage=335&rft.pages=325-335&rft.issn=1359-6101&rft_id=info:doi/10.1016/S1359-6101(03)00028-5&rft_dat=%3Cproquest_cross%3E18797333%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c444t-ff4142d6fec22ee06c0b1bd270485021d341c2a0fe4cc6ddea939f19646617a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=18797333&rft_id=info:pmid/12787569&rfr_iscdi=true |